Selecta Biosciences, Inc.

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

August 16, 2010

Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation

Morphotek, Inc.

Morphotek announces successful development of antibody cell line for Abgenix

Morphotek announces successful development of antibody cell line for Abgenix

December 16, 2003

Exton, PA - December 16, 2003 - Morphotek Inc. announced today that Abgenix, Inc. of Fremont, CA has confirmed the development of an antibody-producing cell line from the companies' research collaboration. The development resulted in an undisclosed milestone payment to Morphotek.

LS9

LS9 Announces Major Scientific Breakthrough Leading to Scalable Production of Low-cost Sustainable Fuels

LS9 Announces Major Scientific Breakthrough Leading to Scalable Production of Low-cost Sustainable Fuels

July 29, 2010

The full LS9 press release is included below. You can find additional coverage of the announcement on:

Venture Beat: LS9 may have just solved biofuels’ scaling problem
Xconomy.com: LS9 Shows Recipe For $50 Oil: Genes That Convert Sugar to Diesel in One Step

Helicos BioSciences Corporation

Helicos Announces Nature Publication on First Evidence of RNA Copying Mechanisms in Human Cells

Helicos Announces Nature Publication on First Evidence of RNA Copying Mechanisms in Human Cells

July 29, 2010

Joint Research with University of Pittsburgh School of Medicine, Integromics, Inc. and the University of Geneva Medical School

Everyday Solutions, Inc.

Everyday Solutions, Inc. Appoints Tom Liebermann Executive Chairman Role

Everyday Solutions, Inc. Appoints Tom Liebermann Executive Chairman Role

July 29, 2010

Concord, MA USA – July 29, 2010 – Everyday Solutions, Inc., the leading provider of integrated solutions for managing School Transportation Information, announced today that Tom Liebermann has been appointed to the role of Executive Chairman of the Board. Mr. Liebermann will lead Everyday Solutions’ Board of Directors, help shape the strategic direction for the company and act as a sounding board for the executive management team on tactical and operational opportunities.

Flagship's Jim Matheson is Entrepreneur in Residence at Lawrence Berkeley National Laboratory

Flagship's Jim Matheson is Entrepreneur in Residence at Lawrence Berkeley National Laboratory

July 26, 2010

Berkeley Lab Gets Its Own Entrepreneur in Residence

JULY 26, 2010, by Julie Chao

VisEn Medical, Inc.

PerkinElmer to Acquire VisEn Medical, Inc.

PerkinElmer to Acquire VisEn Medical, Inc.

August 3, 2010

Global leader in human health and environmental health adds in vivo molecular imaging capabilities for enhancing preclinical research for more effective therapies

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI - News), a global leader focused on the health and safety of people and the environment, today announced that it has acquired VisEn Medical, Inc., an in vivo molecular imaging technology company based in Bedford, Massachusetts.

Black Duck Software, Inc.

Black Duck Wins Best Of Show At Corporate & Channel Computing Expo

Black Duck Wins Best Of Show At Corporate & Channel Computing Expo

June 29, 2006

The protexIP Software Compliance Management Solution Receives Honor for "Hottest New Idea"

Acceleron Pharma, Inc.

Acceleron Pharma Closes $30M Series B Financing

Acceleron Pharma Closes $30M Series B Financing

August 2, 2006

CAMBRIDGE, MA – August 2, 2006 - Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that it secured a $30 million Series B financing. OrbiMed Advisors, the sole new investor, led the round with participation by all existing institutional investors including Advanced Technology Ventures, Flagship Ventures, Polaris Ventures, Sutter Hill Ventures and Venrock Associates. As part of this financing, Carl Gordon, Ph.D. of OrbiMed will join the Board of Directors.

VisEn Medical, Inc.

Olympus and VisEn Medical Sign Exclusive Japanese Distribution Agreement for Near Infrared Fluorescence Probes and Fluorescence Tomographic Imaging Systems

Olympus and VisEn Medical Sign Exclusive Japanese Distribution Agreement for Near Infrared Fluorescence Probes and Fluorescence Tomographic Imaging Systems

August 7, 2006

TOKYO & WOBURN, Mass.--(BUSINESS WIRE)--Aug. 7, 2006--Olympus Corporation (Olympus, President: Tsuyoshi Kikukawa) and VisEn Medical, Inc. (VisEn, CEO: Kirtland G. Poss), today announced that they have signed an exclusive Japanese distribution agreement covering VisEn's fluorescence molecular tomography(TM) (FMT(TM)) imaging systems and portfolio of in vivo near infrared fluorescence probes. Olympus will commence sales of the products from September 1, 2006.